Cipla Ltd Q1 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/ts7tjpj4qz1d9z85dlsccdvr.pdf

Key Takeaways


US Business & Complex Pipeline

Vohra: "I think the market is fairly large for any peptide for the one that are there I think will not be uncommon to see your product in the $35-50 million range, if executed well."

India Business

Vohra: "We are very bullish about this market specially as healthcare deepens in India... we continue to grow significantly higher than market in the trade generic category..."

Margins & Cost Structure

Jain: "The freight cost and other procurement cost related increase, we expect it to continue for some period of time so therefore we want to... give guidance in this range only."

Other Businesses & Geographies

SegmentTrendCommentary
Global Consumer▲ Strong tractionContribution now 9% of overall Cipla revenue; Consumer Health business is now EBITDA positive.
SAGA region▼ Declined 10% YoY ($)South Africa Private business had muted primary sales expected to recover in coming quarters; secondary demand continues with Cipla outperforming the industry.
International Markets▲ Grew 18% YoY ($)Included benefit of last year’s low base from timing deferrals for Middle Eastern supplies; DTM franchise delivered strong double-digit growth offsetting forex volatility and muted B2B demand.
API business▬ NormalizedLast year included a profit share on commercial supply of an API to a partner, recognized in the previous year’s quarter.

Regulatory & Pipeline Updates


Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA marginMaintain 21%–22% range for FY23; freight and procurement cost increases expected to continue, offset by new launchesFY23
R&D spendCloser to 5.5%–6% of revenue for the full year, increasing as clinical trials enroll more patientsFY23
US complex launchesThree significant launches expected: Advair (earlier part of H2), Abraxane (latter part of H2, pending FDA inspection), Revlimid (when market forms per settlement)H2 FY23
Peptide portfolioFirst product to reach teens market share by year-end; one more launch late this year or early next; two more probably late next yearFY23–FY24
India businessContinue to grow higher than the industry; core base market expected to grow about 10% for the full yearFY23
South Africa PrivateMuted primary sales expected to recoverComing quarters
Consumer HealthGrown sustainablyComing quarters

Key Metrics

MetricQ1 FY23
RevenueNot explicitly stated as a consolidated figure
Reported EBITDA₹1,143 cr, 21.3% of sales
Reported EBITDA margin21.3%, tracking in line with full-year guidance of 21%–22%
Core operating profitability growth12%, adjusted for COVID portfolio normalization and API profit share in last year's base
Profit after tax₹686 cr, 12.8% of revenue
Effective tax rate27.5%
Gross margin after material cost62.3%, broadly in line with last year; absorbed 170 bps impact from higher procurement, freight and forex
Total expenses (employee + other)₹2,207 cr, declining 6.6% sequentially
Employee costs₹956 cr, up 7% YoY, driven by increments
Other expenses (R&D, regulatory, quality, manufacturing, sales promotion)₹1,252 cr, declining 15% sequentially
Total R&D spend₹274 cr, 5.1% of revenue; full-year guidance of 5.5%–6%
One-India business growth (ex-COVID)9% YoY, adjusted for COVID portfolio normalization
Global Consumer franchise contribution9% of overall Cipla revenue
Cipla Health annualized franchise (incl. Endura Mass)₹600 cr, well poised to achieve
US core formulation sales$155 million, growth of 10% YoY
DTM Respiratory Franchise growth22% over last year
Generic respiratory market share rankTop three in the US
SAGA region growthDeclined 10% YoY in dollar terms
South Africa private market share7.4%, third position; grew 10.6% vs 7% overall market per IQVIA MAT May 2022
International market business growth18% YoY in dollar terms
Long-term debtZAR 72 cr in South Africa, $7 million in Uganda
Working capital loans$49 million, €3 million, GBP 3 million and others
Other income₹106 cr, higher QoQ due to exchange gain and slightly higher financing income
EBITDA margin adjusted for 170 bps cost impact23% (per an analyst's math)